HEPA Insider Trading
Insider Ownership Percentage: 0.06%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Hepion Pharmaceuticals Share Price & Price History
Current Price: $0.07
Price Change: ▲ Price Increase of +0.004 (5.97%)
As of 12/18/2025 11:24 AM ET
Hepion Pharmaceuticals Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/27/2023 | Peter Wijngaard | Director | Buy | 50 | $152.50 | $7,625.00 | 190 |  |
| 11/24/2023 | Peter Wijngaard | Director | Buy | 50 | $154.50 | $7,725.00 | 140 | |
| 9/19/2023 | Peter Wijngaard | Director | Buy | 20 | $282.00 | $5,640.00 | 90 | |
| 9/18/2023 | Robert T Foster | CEO | Buy | 32 | $280.00 | $8,960.00 | 1,009 | |
| 9/15/2023 | Peter Wijngaard | Director | Buy | 40 | $280.00 | $11,200.00 | 70 | |
| 9/15/2023 | Robert T Foster | CEO | Buy | 32 | $270.00 | $8,640.00 | 977 | |
Hepion Pharmaceuticals Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 5/14/2025 | Anson Funds Management LP | 105,685 | $45K | 0.0% | -54.4% | 0.967% |  |
| 11/15/2024 | Anson Funds Management LP | 231,849 | $0.16M | 0.0% | N/A | 3.331% | |
| 8/15/2024 | Armistice Capital LLC | 516,000 | $0.53M | 0.0% | +32.3% | 9.428% | |
| 2/13/2024 | Armistice Capital LLC | 418,000 | $1.35M | 0.0% | +5.1% | 9.631% | |
| 11/15/2023 | Armistice Capital LLC | 397,607 | $1.98M | 0.0% | N/A | 10.360% | |
| 5/1/2023 | Virtu Financial LLC | 53,501 | $42K | 0.0% | +152.8% | 0.070% | |
| 11/7/2022 | Virtu Financial LLC | 67,802 | $34K | 0.0% | +195.6% | 0.089% | |
| 10/13/2022 | PVG Asset Management Corp | 107,915 | $55K | 0.2% | N/A | 0.142% | |
| 8/12/2022 | Ikarian Capital LLC | 410,189 | $0.24M | 0.0% | -29.5% | 0.538% | |
| 2/4/2022 | Envestnet Asset Management Inc. | 72,027 | $82K | 0.0% | +87.5% | 0.094% | |
| 2/2/2022 | PVG Asset Management Corp | 100,089 | $0.11M | 0.4% | +92.5% | 0.131% | |
| 11/10/2021 | PVG Asset Management Corp | 51,989 | $80K | 0.2% | -72.6% | 0.068% | |
| 11/9/2021 | BlackRock Inc. | 1,634,012 | $2.50M | 0.0% | -1.0% | 2.144% | |
| 11/5/2021 | PNC Financial Services Group Inc. | 39,034 | $60K | 0.0% | N/A | 0.051% | |
Data available starting January 2016
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Read More on Hepion Pharmaceuticals
Volume
1,369 shs
Average Volume
41,931 shs
Market Capitalization
$811.89 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.52
